There are other factors required in addition to trial success in order to make the company valuable. I realize that. I read the annual report's risk factors. Not really different from any other company with one promising therapy. But the subset chosen now has promise based on the prior data, the FDA supports the trial, and insiders are buying. The odds are good. We'll concern ourselves with company business after the trial succeeds. Maybe we'll sell on the pop. After all, that's usually a good idea with these type companies.
"you do realize the final data is not anticipated until mid 2018 right?" Yes, which means that you have a long wait to remain short if you want to make a profit. VTL will not go down, other than for backing and filling, for a long time.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM